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MEETING REPORT
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ABSTRACT
Osteoarthritis (OA) is a major clinical problem across the world, in part due to the lack of disease-
modifying drugs resulting, to a significant degree, from our incomplete understanding of the
underlying molecular mechanisms of the disease. Emerging evidence points to a role of epige-
netics in the pathogenesis of OA, but research in this area is still in its early stages. In order to
summarize current knowledge and to facilitate the potential coordination of future research
activities, the first international workshop on the epigenetics of OA was held in Amsterdam in
October 2015. Recent findings on DNA methylation and hydroxymethylation, histone modifica-
tions, noncoding RNAs, and other epigenetic mechanisms were presented and discussed. The
workshop demonstrated the advantage of bringing together those working in this nascent field
and highlights from the event are summarized in this report in the form of summaries from
invited speakers and organizers.
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Osteoarthritis
Osteoarthritis (OA) is a common, late-onset disease
characterized by the loss of the articular cartilage of
synovial joints. It principally affects the hands, the hips,
and the knees (1). The disease is present throughout the
world and demonstrates a greater prevalence in
females. OA has a profound impact on patient morbid-
ity, with millions of joint replacements for OA per-
formed per year across the globe. The disease also
leads to increased mortality, resulting from secondary
cardiovascular events arising from lower patient activity
(2). The disease is therefore a major global health-care
problem and the burden of OA will continue to rise as
average population age increases (3).
The disease presents clinically as a chronically painful
joint in the absence of any overt inflammation.
Radiographic diagnosis highlights a narrowing of the
joint space as the cartilage begins to focally thin. Other
radiographic features can include the formation of
osteophytes at the margins of the joint and sclerosis of
the underlying bone. The disease therefore affects multi-
ple joint tissues (4), but the loss of the cartilage is pivotal.
There are currently no disease-modifying drugs for
OA, with the only treatment options being analgesia,
physical therapy, weight loss, and ultimately joint repla-
cement. It is imperative therefore that our understand-
ing of the causes of the disease is improved, and in this
regard there has been a tremendous amount of research
activity over the last decade to understand the disease
from a molecular and cellular perspective. Most of these
studies have focused on cartilage and the single cell type
responsible for forming this tissue, the chondrocyte.
A number of insights have emerged from these investi-
gations, including the role of a range of signaling path-
ways in maintaining cartilage integrity, the shift from
anabolism to catabolism that increases disease risk, and
the role of genetic factors in predisposing to OA (5–8).
OA is a particularly polygenic disease, with no risk-
conferring alleles of large singular impact. The disease
does not transmit within families in a Mendelian fash-
ion. Instead, OA presents as a standard multifactorial,
complex trait. The mapping of OA loci has therefore
required the use of large cohorts in case–control asso-
ciation studies. These have taken the form of candidate
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gene-based studies and the hypothesis-free genome-
wide approach, testing hundreds of thousands of sin-
gle-nucleotide polymorphisms (SNPs). So far up to 16
replicated OA susceptibility loci have been detected at
or around the genome-wide significance threshold of p
< 5 × 10−8 (6,8). Functional studies using cell lines and
patient tissues have revealed that effects on gene
expression appear to be a common mechanism by
which risk-conferring alleles mediate their OA suscept-
ibility; clear examples are the OA-associated SNPs
rs143383, rs225014, and rs3204689 and their correla-
tion with expression changes at the genes GDF5, DIO2,
and ALDH1A2, respectively (9–12).
Epigenetics
Epigenetics refers to a heritable change in gene expres-
sion that occurs without a change to the underlying
DNA sequence. There are three known mechanisms of
epigenetic gene regulation: DNA methylation, histone
modifications, and noncoding regulatory RNAs. The
first two mechanisms regulate gene expression by mod-
ulating gene transcription, whereas regulatory RNAs
act post-transcriptionally (13). Epigenetic patterns are
both plastic, especially during development and cell
differentiation when they undergo dynamic changes,
and stable, allowing cellular identity to be maintained
during mitotic cell division. Epigenetics provides the
cell with a mechanism to respond to its environment at
the cellular, tissue, and organismal level.
Epigenetics and OA
During the last few years, there have been a number of
studies undertaken into the role of epigenetics in OA
etiology. These studies started with an investigation of
the epigenetic regulation of the expression of genes
coding for proteins that have a known central role in
the homeostasis of joint tissue, and in particular carti-
lage (14). There have also been direct investigations of
the differences in expression levels of regulatory RNAs
between OA and non-OA cells, the aim being to iden-
tify key RNAs that could initiate or exacerbate disease
development (15,16). The advent of high-throughput
CpG DNA methylation arrays has enabled investigators
to directly compare, at a genome-wide level, OA and
non-OA methylomes and to compare methylation sta-
tus between DNA from different sites within the joint
and between different joints (17–22). These arrays have
also been used to assess whether there are direct links
between OA genetic risk loci and epigenetic status, and
between gene expression and epigenetics (23,24).
The first international workshop on the
epigenetics of OA
The OA epigenetics field is however still quite small
and, like many nascent research areas, lessons are still
being learnt regarding data analysis and interpretation,
and also the sample sizes needed to draw robust con-
clusions. In response to this ongoing epigenetics
research and the likelihood that such research will
play an increasing role in our understanding of this
complex disease, a workshop was organized at the
Dutch Royal Academy of Science in Amsterdam on
the 20th and 21st of October 2015. The aims of the
workshop were to discuss the current status of OA
epigenetics research, to provide overviews of particular
activities, to provide guidance on particular techniques
(the analysis of DNA methylation arrays and of RNA
sequencing data), and to offer a flavor of the status of
epigenetics research in another arthritic disease, rheu-
matoid arthritis (RA). The workshop had 3 organizers
(Frank Beier, John Loughlin, and Ingrid Meulenbelt), 8
invited speakers, and 12 oral abstract presentations
selected from those who registered. In total, 60 scien-
tists from 14 countries and 4 continents gathered to
present and to discuss their OA epigenetics research.
Reumafonds (http://www.reumafonds.nl/) and the
Osteoarthritis Research Society International (http://
oarsi.org/) provided financial support for the
workshop.
This article provides summaries of the presentations
from seven of the invited speakers (Nidhi Bhutani,
Louise Reynard, Andrew Skelton, Udo Oppermann,
David Young, Wouter den Hollander, and Steffen
Gay) and from one of the organizers (Ingrid
Meulenbelt), capturing their key points. Frank Beier
also presents a discussion on higher-order nuclear
organization and OA. The article ends with a look to
the near future of how epigenetics will enhance our
understanding of the causes of this most common of
joint diseases.
Stable cytosine modifications in the OA
epigenome: new kids on the block
DNA methylation on the base cytosine [5-methylcyto-
sine (5mC)] was long-thought to be a stable epigenetic
mark leading to gene silencing (25). Recent studies have
however revealed that DNA methylation is both
dynamic and reversible and have identified the key
enzymes and pathways mediating DNA demethylation
(reviewed in 26). Nidhi Bhutani of Stanford University
presented her groups’ investigations into DNA hydro-
xymethylation on the cytosine (5hmC), which has been
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discovered to be a stable cytosine modification along-
side 5mC and which is now known to be an indepen-
dent epigenetic mark (26,27). The enzyme family that
converts 5mC to 5hmC is the ten-eleven-translocation
(TET) family of proteins consisting of three known
members: TET1, 2, and 3 (27,28). These TET proteins
are also capable of further oxidizing 5hmC to 5-for-
mylcytosine (5fC) and 5-carboxylcytosine (5caC) (29),
intermediates that are acted upon by base excision
repair enzymes like thymine DNA glycosylase, leading
to replacement by an unmodified cytosine and hence
active DNA demethylation (30,31). The precise
mechanisms leading to a stable 5hmC generation or
5caC generation and subsequent demethylation are
however not yet clear.
Over the years, evidence has been accumulating for a
critical role for DNA methylation and demethylation in
OA pathogenesis (32). Alterations in DNA methylation
patterns have been observed in OA chondrocytes, par-
ticularly a loss of DNA methylation at the promoters
and the concurrent “unsilencing” of various OA-asso-
ciated genes including MMP3, 9, and 13, ADAMTS4,
IL-1β, and iNOS (14,33,34). Recently, Professor
Bhutani’s team reported a remarkable dysregulation of
5hmC homeostasis in patients with OA, with increases
in global 5hmC levels observed in OA chondrocytes
when compared to normal chondrocytes (35). 5hmC
gain at specific sites in the promoters of key OA genes
was associated with increased gene expression.
Genome-wide 5hmC distribution in normal and OA
chondrocytes identified a total of 70,591 differentially
hydroxymethylated regions (DhMRs); 44,288 were
increased in the OA chondrocytes as compared to the
normal chondrocytes and 26,303 were decreased (36).
Analysis of the genomic locations of these DhMRs
revealed that the majority of 5hmC gain in OA occurs
in gene bodies. Upon assessing the 5hmC distribution
in the activated or repressed genes, it was observed that
activated genes demonstrated elevated 5hmC in both
the promoter regions and throughout the gene body in
OA chondrocytes in comparison to normal chondro-
cytes, whereas the repressed genes exhibited no signifi-
cant changes (36). In light of these observations, further
studies are required on the distribution of these newly
identified cytosine modifications and their effects on
the OA epigenome and transcriptome.
A major caveat in widely prevalent techniques to
assess DNA methylation, such as bisulfite conversion,
is the failure to distinguish between 5mC and 5hmC
(37). In light of the recent observations regarding a
genome-wide role for 5hmC alterations in OA chon-
drocytes, it is imperative to utilize recently developed
chemical tools that can distinguish between 5mC and
5hmC as well as between the less stable 5fC, 5caC, and
unmethylated cytosines (38). These tools consist of (a)
antibody-based enrichment using specific anti-5hmC,
-5mC, -5fC, and 5caC antibodies and (b) affinity-based
enrichment after specific modifications of 5hmC
(39,40), followed by high-throughput sequencing. In
addition, methods have been developed that can be
used in conjunction with bisulfite sequencing for a
base resolution mapping of 5hmC (TET-assisted bisul-
fite sequencing (41)), 5fC (5fC chemical-modification
assisted bisulfite sequencing (41)), and 5caC (5caC che-
mical-modification-assisted bisulfite sequencing (42)).
Utilizing these tools, it is possible to study precise
genome-wide distribution of these cytosine modifica-
tions in OA joint cells in order to understand how these
stable cytosine modifications and DNA methylation
and demethylation dynamics influence the gene expres-
sion changes observed in OA and other rheumatic
diseases.
Candidate gene analysis of DNA methylation
in OA
The application of measuring DNA methylation con-
tent of CpGs sites at targeted genes was covered by
Ingrid Meulenbelt of the Leiden University Medical
Center. Targeted methylation of CpG sites has been
studied in the context of OA susceptibility genes,
mainly to explore whether the risk-conferring alleles
that were found to influence in cis gene expression act
via modulation of DNA methylation of transcription-
ally active CpG sites that are close to or that are them-
selves SNPs (43,44). Such targeted analysis of
methylation levels at positional CpG sites is typically
performed by subjecting bisulfite converted DNA to
MALDI-TOF mass spectrometry (Epityper, Sequenom;
(45)) or to pyrosequencing (46). Epityper is suitable for
high-throughput analysis, but cannot always capture
every CpG of interest, whereas pyrosequencing is not
suitable for high-throughput analysis but quantification
of methylation at any CpG site is possible.
By applying Epityper analyses of 20 CpG sites that
mapped across the DIO2 locus, it was shown that
methylation at a particular CpG site 2 kb upstream of
the promoter enhanced DIO2 expression, particularly
in carriers of the OA risk C allele of the rs225014 T>C
SNP (43). Since this CpG maps within an active
CCCTC-transcription factor (CTCF) binding site,
methylation-dependent binding of this CTCF is sug-
gested to act as a positional isolator of DIO2 expression
(43). Additionally, by applying pyrosequencing analyses
of methylation at a CpG site located in the 5’ untrans-
lated region of GDF5, it was shown that the OA risk T
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allele of the rs143383 C>T SNP, which had previously
been shown to correlate with GDF5 expression in
articular cartilage (10), disrupts a functional CpG dinu-
cleotide (44). Furthermore, the reported allele-specific
expression (ASE) of GDF5 in heterozygous carriers
marked by the rs143383 alleles is affected by the extent
of methylation of the respective CpG (44). Together,
these studies demonstrated OA risk alleles that confer
susceptibility to OA via changing the epigenetically
modulated gene expression. Nonetheless, genome-
wide analysis of the transcriptome and methylome of
articular cartilage revealed that only 24% of the differ-
entially methylated CpG sites correlated to proximal in
cis gene expression and as such could be considered
transcriptionally active in articular cartilage (19,24).
Moreover, it was shown that for 31 and 26 OA carti-
lage-relevant genes, methylation and expression,
respectively, are additionally affected by genetic varia-
tion proximal to these genes, which may further modify
the OA pathophysiology (19,24).
Methylation microarrays: where to start
Genome-wide studies of the human methylome have
been assisted by microarray technology for a number
of years, with the principal array provider being
Illumina with their HumanMethylation series of
BeadChips. The array platform has grown from 27,578
CpG dinucleotide probes (the 27K chip) covering over
14,000 genes to 485,000 CpG probes (the 450K chip)
covering 99% of the Reference Sequence genes. It is
very important to consider the experimental design
before conducting a methylation array, and in this regard
Louise Reynard and Andrew Skelton of Newcastle
University offered guidance in their presentation. There
are biases between chips and there are positional effects
within a chip, and so even before data have been gener-
ated, samples should be randomized within and across
chips to allow for correction of technical variation. A
phenotype table should also be created, which includes
all relevant sample information (such as gender, cell
type, and any treatment regimen); this table will aid
downstream data analysis. A flow chart listing the main
steps in processing data generated using the Illumina
methylation arrays is shown in Figure 1. The raw data
generated by the Illumina scanners come in a standard
binary format called IDAT files, and there are many
packages available for analyzing these files in
Bioconductor (https://www.bioconductor.org/), an
open-source repository of bioinformatics software
packages that includes Minfi, CHAMP, WateRmelon,
and methylumi (http://doi.org/10.1093/bioinformatics/
btu049, http://doi.org/10.1093/bioinformatics/btt684,
http://bioconductor.org/packages/release/bioc/html/
wateRmelon.html, http://bioconductor.org/packages/2.
8/bioc/html/methylumi.html). Once the IDAT file is
inputted, all packages will recommend a normalization
procedure; this is a mathematical process to make sam-
ples comparable to one another and is crucial. Probe
filtering is an essential step prior to downstream data
analysis. Each probe on the array has a detection p value
based on how confident the intensity call is, and probes
with p values greater than 0.01 should be considered for
removal. Additional probe filtering, for example,
removal of sex chromosome probes or those containing
SNPs, should be considered based on the experimental
design. Leaving in probes containing SNPs with a high
minor allele frequency can lead to data biases, whilst
gender is often an overwhelming source of variation in
methylation studies. Quality control (QC) should be
carried out on all samples to ensure that the data gener-
ated are as expected; the Minfi QC Report tool, or the
MethylAid (http://bioinformatics.oxfordjournals.org/
content/30/23/3435) package, will allow visualization of
potential biases in the experiment, such as bisulphite
conversion and chip hybridization. Additional tools,
such as principle component analysis, are very good at
identifying known technical variation. If samples are
removed for QC reasons, then the normalization and
probe filtering steps must be repeated.
There are two types of metric in methylation micro-
array data, beta values, and M values. Beta values are
between 0 and 1, and are equated to percentage methy-
lation. M values are the log ratio of methylation against
unmethylation intensities. Whilst beta values are useful
for graphical representation and interpretation of the
Raw Data
Pheno Table
Read Raw IDAT
Detection P Val
Normalisation
Normalised
Data
Probe Filtering
Normalised
Filtered Data
QC
Normalised
Filtered Data
Linear Model 
Fit
DM Probes
R
e
m
o
v
e
 S
a
m
p
le
Figure 1. Flow chart of the main steps in analyzing Illumina
DNA methylation array data. QC: quality control; DM: differen-
tially methylated; Pheno: phenotype.
4 I. M. MEULENBELT ET AL.
D
ow
nl
oa
de
d 
by
 [N
ew
ca
stl
e U
niv
ers
ity
] a
t 0
8:4
1 0
3 M
ay
 20
16
 
data, M values should be used for statistical analysis
because of the heteroscedastic nature of beta values,
which leads to increased false positives (47). Linear
models should be used for any differential methylation
tests performed, such as the Limma package, as they
allow the flexibility of simple to complex experimental
designs and can account for identified technical
variation.
As of October 2015, there had been four published
cartilage methylome studies using the 450K array, and
Dr. Reynard and Mr. Skelton have combined data from
three of these (Newcastle, Leiden and Utah; 19–21).
They have a total of 179 cartilage samples composed
of 35 control hips, 39 preserved OA hips, 21 lesioned
OA hips, 73 preserved OA knees, and 11 lesioned OA
knees. Using a Benjamini–Hochberg adjusted p value ≤
0.01 and a Δbeta of ≥0.1, they have identified 3,424
differentially methylated loci (DMLs) between control
hip and OA hip cartilage, and 5,781 DMLs between
preserved OA hip and preserved OA knee cartilage.
These data will form the basis of an OA methylome
database that they are currently establishing, and in the
future, they hope to be able to include methylome data
generated by other groups from within the joint biology
and OA fields.
Histone modifications are critical elements of
the epigenomic landscape: using chemical tools
to interrogate epigenetic biology
The importance of local chromatin structure for con-
trolling gene expression was the focus of the presenta-
tion by Udo Oppermann of the University of Oxford.
Accessible chromatin, such as that found in euchroma-
tin, provides the environment for gene-regulatory pro-
teins such as transcription factors or remodeling
complexes to interact with their cognate binding sites
within the regulatory regions of genes, such as proximal
promoters, enhancers, or silencers (48). For example,
trimethylated lysine 9 of histone 3 (H3K9me3) indi-
cates heterochromatic or repetitive regions, whereas
H3K4me3 marks regulatory elements associated with
active promoters or transcription start sites and
H3K27me3 marks those for developmentally repressed
genes. Modification systems (so-called writers and era-
sers of chromatin marks) that covalently alter specific
residues of chromatin proteins play a pivotal role in
this process and generate a so-called “histone code”
(49) that recruits specifically recognition domains and
components (readers) of transcriptional complexes,
which thus serve as the effectors of the modification.
In this complex and interdependent manner, chroma-
tin-modifying systems exert control of global and local
gene activation. Importantly, histone modifications and
DNA methylation act in concert with respect to gene
regulation because both activities are functionally
linked (50).
At present, several classes of histone modifications
and their respective enzymatic modification systems
have been identified (51–53). Amongst their epigenetic
substrate marks, lysine and arginine modifications are
probably the best studied: acetylation and methylation
of lysine residues, as well as methylation of arginine.
Whereas acetylation of histone tails is correlated with
gene activation, the influence of histone methylation on
regulating gene transcription depends on the exact
residue methylated and the number of added methyl
groups, both for arginine and lysine residues. The
involvement of histone modifications in the regulation
of key aspects of the musculoskeletal system, for exam-
ple, in inflammation or differentiation, has recently
been described (54). The best understood systems of
histone modifications that potentially allow transmis-
sion of stable heritable marks through cell divisions
comprise methylation of H3K9 (HP1, heterochromatin
establishment), and of H3K27 and H3K4 (repression
and activation of genes through polycomb and
trithorax complexes, respectively).
A chemical probe is a reagent that perturbs specifi-
cally a protein’s function and allows the user to ask
mechanistic and phenotypic questions about its mole-
cular target in biochemical, cell-based or animal studies
(55). Chemical probes are impactful and complemen-
tary to genetic approaches, such as CRISPR/Cas and
RNA interference (RNAi). They can rapidly and rever-
sibly inhibit a protein function in cells or animals.
When coupled with RNAi, they can distinguish
between effects due to scaffolding and effects due to
inhibition of catalytic or protein-interaction activity.
These features of chemical probes are relevant for
translational studies and target validation efforts. Such
chemical tools are currently being developed for epige-
netic biology by Professor Oppermann and his collea-
gues at the Structural Genomics Consortium (http://
www.thesgc.org/scientists/groups/oxford), an interna-
tional public–private partnership that promotes open-
access drug discovery and target validation
Higher-order nuclear organization and OA
Another emerging area in epigenetic regulation of gene
expression is the three-dimensional organization of
chromatin in the nucleus, which was described by
Frank Beier of the University of Western Ontario. It
is now well accepted that chromosomes and chromatin
are not randomly distributed in the nucleus, but
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organized in a highly sophisticated manner that is
closely linked to transcriptional activity (56). Such
higher-order organization includes the folding of large
genomic regions, chromatin looping that connects
enhancers and promoters, and interactions of chromo-
somes with the nuclear periphery (e.g., the lamina).
These interactions result in the formation of a number
of domains such as active chromatin hubs, topologically
associating domains (TADs), and lamin-associated
domains (56,57). A number of key proteins mediating
these interactions have been identified, most notably
the previously mentioned factor CTCF and the cohesin
complex (58). The function of these proteins in carti-
lage, other joint tissues, or OA has not been addressed,
although the association of a CTCF binding site with
the before-mentioned DIO2 SNP (43) points toward
important roles.
Moreover, studies on developmental defects in
humans and mice suggest essential functions of CTCF
and its partners in the skeleton. For example, limb-
specific knockout mice for Ctcf completely lack fore-
limbs while their hindlimbs are severely shortened (59).
Similarly, disruption of CTCF-associated TADs in mice
and in human cells has been linked to limb malforma-
tions (60). Finally, mutations in genes encoding cohesin
components give rise to limb malformations (in addi-
tion to other defects) in both human patients and
animal models (61). Given the close links between
skeletal development and OA pathogenesis (62), it is
therefore likely that CTCF and cohesin proteins are
also essential for normal cartilage and joint homeostasis
in the adult. Nevertheless, specific functions of these
proteins and three-dimensional chromatin organization
in the adult joint and in OA have not been reported.
Similarly, specific approaches that have been developed
to examine three-dimensional chromatin interactions,
such as chromatin conformation capture (3C) and its
derivatives (4C, 5C, HiC, etc.) as well as ChIA-PET
(63), have yet to be applied to adult cartilage and
joint tissues.
Regulatory RNAs and OA
The completion of the human genome project revealed
a surprising dearth of protein-coding genes, circa
20,000. However, with the advent of massively parallel
sequencing technologies the complexity of the tran-
scriptome made by the genome is becoming apparent.
The transcriptome now includes 2,588 microRNAs
(small, 22–23 nucleotide long, post-transcriptional reg-
ulators of gene expression), an abundance of other
small RNAs (SnoRNAs, Y RNAs, and Pi-RNAs), and
long noncoding RNAs (lncRNAs), for which over
200,000 isoforms are predicted to exist (64). The role
of such regulatory RNAs in OA was the focus of the
presentation by David Young of Newcastle University.
In terms of microRNAs, miR-140 still represents the
most abundant, cartilage-specific, small RNA. Deletion
of miR-140 in mice causes a shorter skeleton and early-
onset OA (65). MicroRNAs are transcribed as a stem-
loop transcript with a -5p and -3p microRNA, either or
both of which can be functional after processing (13).
Because the miR-140 null mouse lacks both miR-140-
5p and miR-140-3p, it is unclear which is most active in
cartilage. Both are highly induced in a model of
mesenchymal stem cell (MSC) differentiation to chon-
drocytes; however, analysis of the regulated transcrip-
tome leads to the prediction that miR-140-5p is the
dominant microRNA since the transcripts that are
most downregulated are significantly enriched for pre-
dicted miR-140-5p targets (66). In fact, other genes that
are also downregulated, but less robustly so, are actually
predicted targets of a previously undefined variant, or
isomer, of miR-140-3p. This leads to the hypothesis
that miR140-5p is a major factor in chondrogenesis,
while the isomer of miR-140-3p fine-tunes the process.
For lncRNAs, RNA sequencing (RNA-seq) analysis
of cartilage and MSC chondrogenesis has identified
several thousand transcripts, many novel and/or differ-
entially expressed between normal and OA cartilage.
One such novel, cartilage-specific, noncoding RNA,
termed SOX9nc2, is located upstream in the genome
of the gene for the important chondrocyte transcription
factor SOX9. Depletion of the SOX9nc2 transcript, by
RNAi, prevents chondrogenesis and concomitant
induction of SOX9 expression. Stem cell chondrogen-
esis models often require TGFβ and SOX9nc2 appears
to regulate the activity of TGFβ, possibly through reg-
ulating the levels of TGFβ-receptor expression. There
are numerous mechanisms as to how lncRNAs exert
their affects (67,68) and still this requires exploring for
SOX9nc2.
Overall, though chondrocytes as a cell type have
largely been overlooked by large sequencing consortia,
data show they express a wealth of noncoding tran-
scripts (69), many of which appear novel. Future work
will be needed to investigate the function of many of
these in vitro and in vivo.
RNA sequencing
Gene expression microarrays have been utilized in OA
research for a number of years, having yielded valuable
information on transcriptome wide gene expression
measurements of OA affected tissues such as articular
cartilage (70–74), synovium (75–77), and subchondral
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bone (78,79). The accompanying bioinformatic chal-
lenges hereof have now been addressed and multiple
easy-to-use software solutions are currently apparent to
aid in silico experiments for research groups that have
traditionally no background in computational biology
(80,81). Presently, transcriptome-wide gene expression
measurements are increasingly being performed using
sequencing efforts, specifically RNA-seq, as opposed to
microarray-based experiments. RNA-seq was therefore
the focus of the presentation by Wouter den Hollander
of Leiden University Medical Center. RNA-seq offers
increased sensitivity (82), as well as more comprehen-
sive analyses of mechanisms such as alternative splicing
and ASE (83); however, as such it also requires less
convenient bioinformatic tools and might thus be less
accessible for researchers without the computational
know-how. Library preparation, sequencing protocol
and depth, read alignment, and the statistical estima-
tion of gene expression levels substantially influence the
outcome of the respective experiment. While most
bioinformatic practices that involve handling sequen-
cing data are compared against one another somewhat
regularly (84–86), there is no golden rule on when to
implement what solution. Consequently, proper QC is
key to understanding whether a methodological
approach serves the scientific question posed. A fre-
quently used QC tool for sequencing experiments is
FastQC (http://www.bioinformatics.bbsrc.ac.uk/pro
jects/fastqc/), which aims to provide an easily accessible
method to inspect raw, but also processed sequencing
data. It generates, in a modular way, web reports for a
number of statistics such as, but not limited to, per base
sequence quality, nucleotide content, sequence length
distribution, and k-mer content. Generally, upon visual
inspection of FastQC reports, sequencing data need to
be processed so that unique sample adapters and low-
quality base calls among reads are removed prior to
alignment. Again, multiple tools are available that
achieve these objectives (e.g., cutadapt and sickle) and
it should thus ideally be tested what tool performs best
in a given experimental design (e.g., single-end sequen-
cing compared to paired-end sequencing). When one is
certain that the reads are of ample quality to continue,
an aligner must be chosen to explore what regions of
the genome are found to what extent in the mRNA
pool, reflecting gene expression levels. As opposed to
aligning DNA sequencing data that can theoretically
cover regions across the entire genome, RNA-seq data
inherently only consist of exon reads. As a consequence
of that, read aligners must be aware of the fact that a
substantial number of reads from an RNA-seq experi-
ment might consist of multiple exons, which are by
definition not directly adjacent to one another on the
genome. As RNA-seq is becoming more common in
transcriptome studies, currently multiple aligners sup-
port alignment of so-called split reads (e.g., BWA (87),
TopHat2 (88), GSNAP (89), and Bowtie2 (90)), but
differ in the underlying method. Aside from the aligner
used, it is important that a proper reference genome to
align against must be chosen. Whereas general refer-
ence genomes like hg19 or hg38 serve their purpose in
RNA-seq experiments to estimate gene expression
levels, when one is interested in alternative splicing
and/or ASE it should be noted that genetic variation,
and likely RNA editing even more so, considerably
influences whether reads will be aligned properly and
must thus be addressed (91).
Epigenetics of RA
Based on the previous observation from his laboratory
that synovial fibroblasts (SFs) from patients with RA
can invade into cartilage without the stimulating influ-
ence of immune cells and proinflammatory cytokines
(92), Steffen Gay of University Hospital Zurich tasked
his group with searching for the causes of this aggres-
sive behavior.
Since his group and others could demonstrate that
synovial fibroblasts in RA (RASF) are not only effector
cells responding to pro-inflammatory cytokines, but act
endogenously when activated, they searched for the
epigenetic modifications leading to the activated phe-
notype of these RASF; this search could also identify
novel targets (93). As early as the year 2000, they had
discovered that RASF are hypomethylated and thereby
endogenously activated through the upregulation of
matrix-degrading enzymes and potent chemokines
(94). This led his laboratory to focus on epigenetics
(95) including histone acetylation, methylation, sumoy-
lation, and noncoding RNAs. This research was and
still is supported by a number of European
Commission grants with closely collaborating centers
throughout Europe, including the consortia Autocure,
Masterswitch, Osteoimmune, TEAM, and BeTheCure.
His group’s most recent research has focused on the
analysis of methylation of novel transcription factor
genes. Thereby they have shown that the promoter of
TBX5 is hypomethylated in RASF and induces the
activation of these cells to produce proinflammatory
cytokines and chemokines including IL8, CXCL12,
and CCL20 (96). His colleague Michel Neidhart has
further analyzed polyamine metabolism in RASF and
developed a novel therapeutic strategy to inhibit one of
the key enzymes regulating methylation (97).
Since RASF are modified in their state of acetylation
through the expression of specific bromodomains
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(acetyl lysine binding domains), another colleague of
Professor Gay, Kerstin Klein, has studied these bromo-
domains, which are involved in chromatin remodeling
and transcriptional activation. She has discovered that
BRD2-4 could be inhibited with BET-inhibitors, which
are currently of interest to a number of global pharma-
ceutical companies (98).
A detailed analysis by two further colleagues of
Professor Gay, Caroline Ospelt and Mojca Frank-
Bertoncelj, of microRNAs and lncRNAs revealed differ-
ences in the transcriptome of SFs that is dictated by joint-
specific positional differences in the origin of the cells.
This could be a contributing factor to RA and was pre-
sented as a plenary lecture at the 2014 annual meeting of
the American College of Rheumatology (99). A complete
analysis of microRNA profiling in RASF versus normal
SFs has been undertaken by his group and the role of
specific microRNAs further identified. For example,
miR-155 is expressed at a higher level in monocytes
than in RASF (100) and has a pivotal role in collagen-
induced arthritis (101). Moreover, his group demon-
strated that miR-203 is regulating IL-6 (102) and that
miR-18a enhances not only the IL-6-mediated produc-
tion of the acute-phase proteins fibrinogen and haptoglo-
bin in human hepatocytes (103), but also, when induced
by TNFα, activates RASF through a feedback loop in NF-
κB signaling (104). His group has also shown that the
targeting of microRNAs by antago-miRs can be highly
effective (105) with, for example, miR-20a inhibited by an
antago-miR for the treatment of pulmonary hypertension
(106). Last but not least, his group has also shown that
miR-323 regulates TIMP3 and thereby inhibits the acti-
vation of the highly potent proinflammatory cytokines
TNFα and IL-6, providing a novel strategy to inhibit both
the cytokine-dependent and the cytokine-independent
pathways of RA.
Conclusions and perspectives
As shown in numerous talks at the workshop, there is
very strong evidence for a key role of epigenetic mechan-
isms in the pathogenesis of OA. This raises hopes that
drugs targeted at specific epigenetic regulators (many of
which are currently under development for the treatment
of cancer and other diseases) might be useful in the
treatment of OA. However, research in this area is still
at an early stage, with mechanistic links between specific
epigenetic changes and disease progression still unclear
in many cases. As was observed in the analysis of OA
genetics, the stratification of OA phenotypes by, for
example, severity of disease, site of disease, and the
involvement of other clinical parameters may aid the
identification of epigenetic markers. An additional lesson
from the genetic studies is the need to study large sample
sizes, although the tens of thousands needed in GWAS
are unlikely to be necessary for epigenetic studies, with
several hundred well-phenotyped samples being a more
realistic target number at this stage. Although the major-
ity of OA epigenetics research has been cartilage-centric,
other relevant joint tissues are being investigated (107)
and this joint-wide approach will be of great value in
elucidating both tissue-specific and joint-wide epigenetic
effects. With regard to pain, which is the number one
complaint of OA patients, epigenetic changes in the
nervous system should also be considered, especially
since the chronic pain in these patients suggests an epi-
genetic component.
Whilst a tremendous amount therefore remains to be
done, the workshop did highlight a number of advances
and was a great success in bringing scientists and trainees
with interests in this area together to discuss future plans.
The requirement to share resources, knowledge, and
expertise was a strikingly clear conclusion and has already
led to the very tangible outcome of the OA methylome
database that was discussed earlier. It is hoped that this
OA epigenetics workshop will be the first of many; a
desire for future workshops will be a mark of advance-
ment in this important OA research field.
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